FDA Approves Second CAR T-Cell Dose for Ovarian Cancer Patient
What happened
The U.S. Food and Drug Administration has approved a second dose of a novel CAR T-cell therapy for a patient with recurrent ovarian cancer. The approval was granted under an individual patient investigational new drug (IND) application, underscoring a personalized approach to advanced cancer treatment.
Why it matters
- The therapy is a "living drug" where a patient's own T-cells, a type of immune cell, are collected and genetically engineered in a lab. A new gene instructs the T-cells to produce specific proteins called chimeric antigen receptors (CARs) on their surface. - These engineered CARs are designed to recognize and bind to a specific protein, or antigen, on the surface of cancer cells, marking them for destruction. In this ovarian cancer trial, the CAR T-cells target the follicle-stimulating hormone receptor (FSHR), a molecule found on ovarian cancer cells. - The entire process can take several weeks; after T-cells are collected from the patient's blood via a process called apheresis, they are sent to a lab for modification and multiplication into hundreds of millions of cells. Before the infusion, the patient typically receives chemotherapy to deplete existing lymphocytes and help the new CAR T-cells proliferate. - The approval for a second dose came through an individual patient Investigational New Drug (IND) application, a pathway that allows patients with life-threatening conditions to access experimental treatments. The process requires a physician to get agreement from the drug manufacturer and then formal FDA authorization, which is granted for over 99% of such requests. - While promising, CAR T-cell therapy can have significant side effects, including cytokine release syndrome (CRS), where the ramped-up immune system causes high fever, and neurological toxicities that can lead to confusion or seizures. - The clinical trial for this specific therapy is a Phase 1 study, which is primarily designed to evaluate the treatment's safety and determine the maximum tolerated dose. The trial has been testing escalating dose levels in different patient cohorts. - This field involves a diverse range of careers beyond direct patient care. Professionals in biotechnology and life sciences are crucial for operating manufacturing equipment, developing new cellular therapies, and ensuring regulatory compliance in the lab. Clinical research teams, including physicians and scientists, design and run the trials to test these new treatments.
Key numbers
- The process requires a physician to get agreement from the drug manufacturer and then formal FDA authorization, which is granted for over 99% of such requests.
- The clinical trial for this specific therapy is a Phase 1 study, which is primarily designed to evaluate the treatment's safety and determine the maximum tolerated dose.
What happens next
- In this ovarian cancer trial, the CAR T-cells target the follicle-stimulating hormone receptor (FSHR), a molecule found on ovarian cancer cells.
Quick answers
What happened in FDA Approves Second CAR T-Cell Dose for Ovarian Cancer Patient?
The U.S. Food and Drug Administration has approved a second dose of a novel CAR T-cell therapy for a patient with recurrent ovarian cancer. The approval was granted under an individual patient investigational new drug (IND) application, underscoring a personalized approach to advanced cancer treatment.
Why does FDA Approves Second CAR T-Cell Dose for Ovarian Cancer Patient matter?
The therapy is a "living drug" where a patient's own T-cells, a type of immune cell, are collected and genetically engineered in a lab. A new gene instructs the T-cells to produce specific proteins called chimeric antigen receptors (CARs) on their surface. These engineered CARs are designed to recognize and bind to a specific protein, or antigen, on the surface of cancer cells, marking them for destruction. In this ovarian cancer trial, the CAR T-cells target the follicle-stimulating hormone receptor (FSHR), a molecule found on ovarian cancer cells. The entire process can take several weeks; after T-cells are collected from the patient's blood via a process called apheresis, they are sent to a lab for modification and multiplication into hundreds of millions of cells. Before the infusion, the patient typically receives chemotherapy to deplete existing lymphocytes and help the new CAR T-cells proliferate. The approval for a second dose came through an individual patient Investigational New Drug (IND) application, a pathway that allows patients with life-threatening conditions to access experimental treatments. The process requires a physician to get agreement from the drug manufacturer and then formal FDA authorization, which is granted for over 99% of such requests. While promising, CAR T-cell therapy can have significant side effects, including cytokine release syndrome (CRS), where the ramped-up immune system causes high fever, and neurological toxicities that can lead to confusion or seizures. The clinical trial for this specific therapy is a Phase 1 study, which is primarily designed to evaluate the treatment's safety and determine the maximum tolerated dose. The trial has been testing escalating dose levels in different patient cohorts. This field involves a diverse range of careers beyond direct patient care. Professionals in biotechnology and life sciences are crucial for operating manufacturing equipment, developing new cellular therapies, and ensuring regulatory compliance in the lab. Clinical research teams, including physicians and scientists, design and run the trials to test these new treatments.
